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Preoperative risk assessment is an important com-
ponent of the overall management of patients under-
going major vascular surgery. Abdominal aortic
aneurysm (AAA) repair, in particular, carries an
increased risk for morbidity and mortality and such
patients consume a relatively large proportion of
health care resources. Despite aggressive diagnostic
and therapeutic manoeuvres, cardiac-related morbid-
ity and mortality still account for the bulk (up to 40%)
of operative mortality after elective infrarenal aortic
reconstruction.1 The level of cardiac risk may be
assessed clinically by the vascular surgeon, anaesthe-
tist, cardiologist, referring doctor, or general practi-
tioner. However, two surveys from the U.K. and one
from the U.S.A. have shown that there is significant
diversity of practice amongst different vascular units
and uncertainty to whether stratification of the cardiac
risk is necessary, how it should be assessed, and how
to use the results to modify the perioperative manage-
ment.2±4 Furthermore, the assumption that more infor-
mation about the patient's cardiovascular status leads
to improved care and, in turn, to improved postopera-
tive results, is unproven. D'Angelo et al. suggested
that cardiac work-up in patients with AAA contri-
butes little and is, therefore, usually unnecessary.5
On the contrary, Fleisher et al. reviewing the data of
Medicare beneficiaries undergoing major vascular
surgery noted a reduced perioperative and long-term
mortality in patients who had previously undergone
preoperative cardiac assessment, in comparison with
those not submitted to preoperative cardiac testing.6
The modern era of coronary risk assessment in vas-
cular surgery patients can be traced back to a classic
study from the Cleveland Clinic.7 In a prospective
series of 1000 patients presenting for peripheral
vascular interventions and undergoing coronary
angiograms, nearly two-thirds of patients with an
AAA had significant coexistent coronary artery dis-
ease (CAD). However, coronary angiography as a
screening test prior to AAA surgery is neither prac-
tical nor ethical. In the last two decades, numerous
studies have attempted to identify patients at cardiac
risk by using costly specialized cardiac investigations,
but uniform use of such testing has not been
achieved.2±4
Patients at risk for perioperative cardiac complica-
tions can be identified by either historical information
or specific testing in preparation for surgery. Several
scoring systems for assessing a patient's cardiac risk
incorporating known risk factors and markers of CAD
have been developed over the years. The multifactor-
ial Goldman cardiac risk index, the Detsky modifica-
tion of the original Goldman index, and the Larsen
index are all useful in stratifying risk and predicting
cardiac complications, but their use in clinical practice
has been limited by the incomplexity. Diagnosing the
third heart sound, an important marker for heart fail-
ure scoring 11 points in the Goldman index, or sus-
pecting critical aortic (valve) stenosis, scoring 20
points in the Detsky index, may not be every vascular
surgeon's `` forte''. This may influence the prognostic
value of the score. It appears that patients with high
scores (Goldman index412 or Detsky index415) are
at higher risk for cardiac complications after vascular
surgery, whereas the indices were found to underesti-
mate the risk associated with abdominal aortic sur-
gery in patients with low overall scores.8 This may
reflect the fact that the indices have been developed
in the general surgical population with only a small
proportion of patients undergoing vascular surgery.
However, the recently revised Goldman cardiac risk
index looks very appealing.9 It has incorporated only
six factors: high-risk type of surgery, history of CAD,
congestive cardiac failure, previous stroke or TIA,
insulin-dependent diabetes, and creatinine42 mg/dl
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(177 mmol/l). Those with 52 risk factors are at very
low risk of postoperative cardiac complications,
whilst those with 2 risk factors have a 6% risk of
cardiac events. This revised index is simple and can be
readily incorporated into routine clinical practice with
minimum resource implications. It has also proved to
be more accurate than other published algorithms and
has identified a larger percentage of patients as having
intermediate or high risk. POSSUM scoring and its
(P- or V-) modifications, using 12 physiological and
six operative variables, may also give a calculated risk
of morbidity and death. Although designed specific-
ally for use in comparative surgical audit, POSSUM
may also be used, on an individual level, for predic-
tion of an adverse outcome, including cardiac compli-
cations or death. As intraoperative factors form an
integral part of this scoring system, the complete POS-
SUM score is not available until after the operation,
and, therefore, its value as a preoperative risk assess-
ment tool is inherently limited. However, a recent
audit of the Vascular Surgical Society of Great Britain
and Ireland, demonstrated that even the preoperative
physiology scores alone could predict death and
major morbidity after arterial reconstruction.10
Specialised cardiac testing has also been evaluated
for the potential to further stratify risk, the `` ideal''
test, however, has yet to be defined. Exercise-ECG
testing is useful in the non-operative setting, but it
may be unhelpful as a preoperative cardiac risk
assessment tool since many vascular patients are
unable to exercise or reach 85% of the maximum pre-
dicted heart rate. Other approaches that have been
used are ambulatory ECG assessments of arrhythmias
and ischaemia, resting or dobutamine-stress echo-
cardiography, and radionuclide studies, such as the
resting or stress multiple gated acquisition (MUGA)
scanning and myocardial perfusion imaging. One
meta-analysis of 20 studies looked at dipyridamole-
thallium scintigraphy, resting MUGA scanning,
ambulatory ECG, and dobutamine-stress echocardio-
graphy, to determine which test was the most effective
in predicting adverse cardiac outcome after vascular
surgery.11 The data were not definitive in determining
the optimal test because the confidence intervals
overlapped, but dobutamine-stress echocardiography
had the highest predictive value. Similarly, in a recent
study of more than 2000 patients undergoing
major vascular surgery, Kertai et al. compared the
prognostic value of dobutamine-stress echocardio-
graphy, dipyridamole-stress echocardiography and
dipyridamole-thallium scintigraphy in predicting
cardiac complications.12 Both stress echocardiography
tests were equally effective in stratifying cardiac risk,
whereas perfusion scintigraphy had a significantly
lower prognostic value.
Nowadays, many vascular surgeons adopt a
Bayesian approach using a combination of clinical cri-
teria and selective functional cardiac testing in order to
improve risk stratification. Venzetto et al. showed that
the addition of the results of thallium scanning to
clinical data significantly increased the ability to pre-
dict a perioperative cardiac event.13 Recently,
Poldermans et al. used stress echocardiography to fur-
ther stratify patients judged as being high risk accord-
ing to clinical criteria.14 Combining the new Revised
Cardiac Risk Index with MUGA scanning has also
been shown to improve cardiac risk stratification.15
The enormous medicolegal and economic implica-
tions of perioperative risk management in patients
with CAD, the availability of multiple technologies
with which to evaluate risk, the diversity of practice
amongst different vascular units, and the confusion
surrounding the goals of perioperative assessment,
prompted the American College of Cardiology/
American Heart Association (ACC/AHA) and the
American College of Physicians to produce clinical
practice guidelines so that rational use of the above
investigations is achieved.16,17 Nowadays, particular
emphasis is given on clinical parameters routinely
available during the preoperative evaluation, and,
less so, on specialised testing. This aims at identifying
patients who may benefit from a specific cardiac
treatment, while avoiding unnecessary, costly and
potentially hazardous cardiac investigations. These
guidelines are based on evidence from cohort studies
and expert opinion and seem to be effective for strati-
fying cardiac risk prior to abdominal aortic surgery.18
Ideally, these recommendations should be tested pro-
spectively by randomised clinical trials; as yet, there
are no such trials published.
According to these guidelines, the preoperative car-
diac evaluation and management of surgical patients
should be a stepwise process based upon the presence
or absence of clinical predictors of cardiovascular risk,
the patient's functional capacity, and the magnitude of
surgery (Fig. 1).17 Because of the profound metabolic
and haemodynamic changes that occur during aortic
cross-clamping and unclamping, abdominal aortic
surgery is considered high-risk for cardiac complica-
tions. The estimation of the patient's functional cap-
acity, i.e. the ability to perform the functions of daily
living, also represents an important aspect of evaluat-
ing overall cardiac risk. This can be easily assessed by
a carefully obtained history and the estimated energy
requirements for various activities can be calculated
by the Duke Activity Status Index.17
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Undoubtedly, the implementation of a cardiac
risk assessment protocol in a vascular unit has no
clinical value unless the perioperative management
is influenced by the results of these investigations.
Even if it is possible to identify or quantify the risk
accurately, however, there is little point in the exercise
unless effective strategies exist for managing patients
at risk.19 So, what available management strategies
are there for those patients deemed to be at an
increased cardiac risk? Invasive intraoperative moni-
toring with pulmonary artery catheters and preopera-
tive haemodynamic `` tune-up'' has not been proved to
have a beneficial effect on outcome.20±22 In terms of
postoperative monitoring, abdominal aortic surgery
patients typically receive postoperative care in an
intensive care environment, however, no randomised
trials have addressed the value of this policy. As
many postoperative cardiac events are `` silent'' and
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Fig. 1. ACC/AHA algorithm for cardiac risk stratification adapted specifically for abdominal aortic aneurysmectomy. (i) Major clinical
predictors of cardiac risk: unstable coronary syndromes, including recent (51 month earlier) myocardial infarction, decompensated
congestive heart failure, significant arrhytmias, severe valvular disease, (ii) intermediate predictors: mild angina, previous myocardial
infarction, compensated or previous congestive heart failure, diabetes mellitus, renal insufficiency, and (iii) minor predictors: advanced age,
abnormal ECG, rhythm other than sinus, low functional capacity, history of stroke, uncontrolled systemic hypertension. Functional status
can be expressed in metabolic equivalent (MET) levels and has been defined as `` good'' or `` moderate'' when the patient could reach a
metabolic demand of at least 4 METs and `` poor'' when exercise capacity is 54 METs or could not reliably be evaluated. One MET is the
oxygen consumption of a 70 kg, 40-year-old man at rest and equals 3.5 ml/kg per min.
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preceded by ischaemic ST segment abnormalities, it
may be possible (by continuous bedside or ambula-
tory ECG monitoring in the postoperative period) to
detect and then treat this myocardial ischaemia, and
thereby reduce the overall incidence of myocardial
infarction. However, this hypothesis has not been
proved in practice.23 Similarly, advocating a more
intensified strategy for surveillance and diagnosis of
perioperative myocardial infarction, for example rou-
tine screening with newer cardiac enzymes, such as
cardiac troponin I and T, may lead to an earlier and
more accurate diagnosis of perioperative myocardial
injury. Again, it remains uncertain whether an earlier
diagnosis and therapy could be translated into better
results in terms of cardiac morbidity and mortality. So
far, the presence of a dedicated intensivist who makes
daily rounds may be the only approach to monitoring
for which there is evidence that improves patient
outcomes after abdominal aortic surgery.24
Although vascular surgery among patients with
prior coronary artery bypass grafting is associated
with a reduced cardiac risk,6,25 the role of prophylactic
preliminary coronary bypass surgery in order to
enable the patient to `` get through'' the vascular sur-
gery remains controversial, largely due to the absence
of prospective randomised clinical trials.26 Hence,
coronary artery bypass surgery should be performed
only if it is indicated on its own merit. On the other
hand, it is the presence of CAD and not necessarily
preexisting critical stenosis that is the substrate for
perioperative ischaemic cardiac events. Therefore,
prophylactic coronary revascularisation may not pre-
vent a perioperative myocardial infarction due to dif-
fuse CAD or the unpredictable progression of
coronary plaques. There have been few studies inves-
tigating the potential protective role of preoperative
coronary angioplasty and/or stenting in vascular sur-
gery, but there are insufficient data to form firm pos-
ition on their role. Currently, the guidelines
recommended are the same as in the non-operative
setting.
When planning the subsequent aneurysm surgery it
is also necessary to consider the timing of these inter-
ventions. There might be a window for surgery the
first few months after successful angioplasty, but fac-
tors, such as the need for antiplatelet therapy post-
angioplasty, the risk of restenosis, and the ongoing
remodelling of coronary arteries, which continues for
several weeks, must be considered carefully. Coronary
stenting also poses unique clinical problems because
of the risk of coronary thrombosis and bleeding in the
postoperative period.27 Post-stenting patients currently
receive a combination of aspirin and clopidogrel for
four weeks, followed by aspirin for an indefinite per-
iod. Kaluza et al. reported catastrophic results when
undertaking noncardiac surgery soon after coronary
stenting and, therefore, recommendations could be
made to wait for at least two weeks, and preferably
four weeks, before attempting aneurysm repair.28
Lastly, little is known about the safety of continuing
antiplatelet agents in patients undergoing elective
abdominal aortic surgery. Neilipovitz et al. suggested
that continuing aspirin in patients undergoing infra-
inguinal arterial surgery would be expected to
decrease preoperative mortality from 2.78 to 2.05%
and increase life expectancy but would also be
expected to increase nonfatal haemorrhagic complica-
tions by 2.46%.29 Extrapolating these data to AAA
repair, an operation associated with greater blood
loss, the potential benefits of antiplatelet therapy
must be weighed against the risk of bleeding. Conti-
nuing aspirin perioperatively may also limit the use of
epidural anaesthesia and analgesia, because of the risk
of an epidural haematoma.27
Endovascular aneurysm repair may also be an
attractive option in reducing cardiac complications as
it allows exclusion of the aneurysm without a laparo-
tomy or prolonged aortic occlusion. Because of its
`` minimally invasive'' nature, endovascular aneurysm
repair may be particularly useful for high-risk
patients, and in many centres EVAR has been offered
to patients who were not considered to be candidates
for conventional repair. However, the RETA database
shows the 30-day mortality rate in unfit patients to be
18%, a figure which raised to 66% when conversion
to open repair was necessary.30 Even after successful
endovascular aneurysm exclusion, data from the
EUROSTAR registry show that more than 20% of
these high-risk patients die within one year, and,
therefore, do not benefit from aneurysm repair.31
However, conclusive evidence is lacking. Multicentre
randomised trials are underway and until the results
are known, endovascular repair in high-risk patients
should be considered cautiously.
To date, of all the available risk-reducing periopera-
tive policies, the routine use of beta-blockers may
represent the single, simple, most efficient measure
to improve outcome in all patients undergoing major
vascular surgery.14,32 Despite the strong evidence,
however, they are still `` incredibly underutilised''.33
The main reason seems to lie in a misconception of
their risk-benefit ratio. Traditional medical teaching
advocates that beta-blockers are contraindicated in
patients with heart failure and those with asthma.
Nevertheless, beta-blocker therapy was recently
found to dramatically improve prognosis in patients
with heart failure.34 As a result, this original major
contraindication has now become a major indication
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for beta-blockers. Similarly, in a recent study of over
200 000 post-myocardial infarction patients, Gottlieb
et al. demonstrated that chronic obstructive airways
disease should no longer be regarded as a contraindi-
cation.35 There is indeed a risk for aggravating left
heart failure or worsening airways obstruction in asth-
matics, but the minority of patients who are intolerant
of beta-blockers can be readily identified preopera-
tively by a test dose of a cardioselective beta-blocker,
such as bisoprolol, atenolol, or metoprolol.36 Another
reason for the under-utilisation of beta-blockers
perioperatively is that the exact timing, dosage, and
duration of therapy remain uncertain. Ideally,
beta-blocker therapy should be initiated several days
or weeks preoperatively, so that the dose can be
adjusted to achieve a resting heart rate of no more
than 60 beats per min.27 Some prefer to use shorter-
acting cardioselective beta-blockers, such as metopro-
lol (25 to 50 mg twice daily), so that the dose can be
adjusted over a period of several days. Beta-blockers
are cheap and safe, and, as such, their perioperative
use should be encouraged.36 Vascular surgeons
should take more responsibility for initiating such
therapy in their patients.
Finally, delay of surgery and ultrasonographic sur-
veillance of a smaller AAA, or even cancellation of the
operation altogether, when the cardiac risks are so
high that they outweigh the risk of rupture, may be
advocated in the very high-risk patients, such as those
with inoperable CAD and/or severe left ventricular
dysfunction. It should be remembered that the prog-
nosis in these patients is very poor. Goldman calcu-
lated that high-risk candidates for AAA repair, such as
those in class IV (Goldman index score426), have a
75% probability of adverse cardiac outcome.37 Because
aneurysms are asymptomatic and the aim of elective
aneurysmectomy is the prolongation of life, it may be
that patients would do better without us intervening
on either asymptomatic condition when discovered to
have a high cardiac risk.
For many patients, the proposed vascular surgery
often represents their first opportunity for an appro-
priate assessment of both short- and long-term cardiac
risk. This is particularly important for `` prophylactic''
operations, such as elective AAA repair. In the current
era of clinical governance, vascular surgeons and
clinicians involved in the management of vascular
patients all need to make informed judgments about
the perioperative risk. Also, patients and their rela-
tives may want to know the risks that surgery entails,
and it is appropriate that a patient with a significant
chance of morbidity and mortality is aware of that
preoperatively.23 Nevertheless, even though many
problems may be identified in the preoperative
phase, there is no reasonable way to entirely eliminate
the possibility that a given patient will suffer a severe
cardiac complication during or immediately following
surgery. Low and high-risk patients should be identi-
fied by clinical assessment. In those with intermediate
risk as judged by clinical evaluation, additional non-
invasive tests for ischaemia and measurements of left
ventricular ejection fraction can further stratify risk,
but should only be reserved for cases in which the
results will be critical in guiding therapy. Despite the
extensive research that has been devoted to develop-
ing the tools to quantify the potential risks of major
vascular surgery, reducing postoperative morbidity
and mortality from CAD continues to be a major chal-
lenge. Future clinical research with well-designed stu-
dies should determine both the cost-effectiveness of
preoperative risk stratification testing and the poten-
tial role of different strategies to reduce cardiac risk.
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